AffaMed Digital is a wholly-owned subsidiary of AffaMed Therapeutics, dedicated to develop and commercialize evidence-based, clinically evaluated digital therapeutics and diagnosis systems for ophthalmic, neurological, and psychiatric disorders, either as stand-alone novel treatment options, or in concert with other therapies to optimize patient care and health outcomes. We develop novel digital therapeutic programs for the treatment of Post Stroke Cognitive Impairment (PSCI) and other indications in collaboration with Beijing Infinite Brain Technologies. Affamed Digital will continue to build robust digital medicines pipeline through partnerships and in-house research.